New Two-Drug attack on blood cancer shows promise
NCT ID NCT06637501
Summary
This study is testing whether adding an experimental drug called sonrotoclax to an approved drug, zanubrutinib, works better than zanubrutinib alone for adults newly diagnosed with chronic lymphocytic leukemia (CLL). About 94 participants will be randomly assigned to receive one of the two treatment plans. The main goal is to see if the combination helps more people achieve a deep response, meaning no detectable cancer or significant improvement, and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aoor Villa Sofia Cervello
Palermo, 90146, Italy
-
Aou Careggi, Servizio Sanitario Toscana
Florence, 50134, Italy
-
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, 25123, Italy
-
Centro de Pesquisas Oncologicas Cepon
Florianópolis, 88034-000, Brazil
-
Cleveland Clinic Florida
Weston, Florida, 33331-3609, United States
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital de Cabuenes
Gijón, 33394, Spain
-
Hospital de Clinicas de Porto Alegre
Porto AlegreRS, 900350-903, Brazil
-
Illinois Cancer Specialists (Niles) Usor
Niles, Illinois, 60714-5905, United States
-
Instituto Dor de Pesquisa E Ensino Sao Paulo
São Paulo, 04501-000, Brazil
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130-2042, United States
-
Nebraska Cancer Specialists (Satellite Site)
Omaha, Nebraska, 68130-2042, United States
-
New York Cancer and Blood Specialists
Shirley, New York, 11967, United States
-
Northwest Georgia Oncology Centers Marietta
Marietta, Georgia, 30060-1152, United States
-
Oncology Associates of Oregon Willamette Valley Cancer Center
Eugene, Oregon, 97401, United States
-
Pratia McM Krakow
Krakow, 30-727, Poland
-
Pratia Onkologia Katowice
Katowice, 40-519, Poland
-
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, 05652-900, Brazil
-
Texas Oncology Dfw
Dallas, Texas, 75231-7001, United States
-
Texas Oncology Tyler
Tyler, Texas, 75702-7522, United States
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, 213000, China
-
Universita Degli Studi Di Modena Azienda Ospedaliere Policlinco
Modena, 41124, Italy
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201-1544, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Uniwersytecki Szpital Kliniczny Hematology
Wroclaw, 50-367, Poland
-
Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
Lublin, 20-090, Poland
-
Utah Cancer Specialists
Salt Lake City, Utah, 84107, United States
Conditions
Explore the condition pages connected to this study.